✦ LIBER ✦

Treatment of Parkinson's syndrome with l-DOPA on an out-patient basis

✍ Scribed by Clas Fehling

Publisher: Springer
Year: 1972
Tongue: English
Weight: 707 KB
Volume: 202
Category: Article
ISSN: 0340-5354
DOI: 10.1007/bf00316221

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5-Hydroxyindoleacetic acid in cerebrospi

5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L-DOPA

✍ B. Johansson; B. E. Roos 📂 Article 📅 1971 🏛 Springer 🌐 English ⚖ 529 KB

Reversible spastic and pyramidal tract s

Reversible spastic and pyramidal tract signs in a patient with parkinson's disease on L-Dopa

✍ Sepp Seyfert; Max Straschill 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 201 KB

Idazoxan, an alpha-2 antagonist, and L-D

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc

Intravenous boluses and continuous infus

Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease

✍ Dr. F. Stocchi; S. Ruggieri; A. Carta; J. Ryatt; N. Quinn; P. Jenner; C. D. Mars 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

## Abstract In six patients with Parkinson's disease exhibiting severe “on‐off” phenomena, a 200‐mg intravenous bolus of either L‐DOPA or of its methyl ester were equally effective in reversing motor deficits, although the duration of action of the methyl ester was shorter. There were no marked dif

Broad bean (Vicia faba)—A natural source

Broad bean (Vicia faba)—A natural source of L-dopa—Prolongs “on” periods in patients with Parkinson's disease who have “on–off” fluctuations

✍ Hülya Apaydin; Sibel Ertan; Sibel Özekmekçi 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Somatostatin-like immunoreactivity, its

Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease — effect of L-Dopa

✍ M. Strittmatter; G. F. Hamann; D. Strubel; H. Cramer; K. Schimrigk 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 826 KB